{"id":"bgb-15025","safety":{"commonSideEffects":[{"rate":null,"effect":"Differentiation syndrome"},{"rate":null,"effect":"Cytopenias (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Menin is a scaffolding protein that interacts with MLL complexes to drive oncogenic gene expression in leukemias with MLL rearrangements or NPM1 mutations. By blocking this menin-MLL interaction, BGB-15025 suppresses the transcription of leukemogenic genes including HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemic cells. This mechanism is particularly effective in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with these genetic alterations.","oneSentence":"BGB-15025 is a selective inhibitor of menin that disrupts the interaction between menin and mixed-lineage leukemia (MLL) proteins, restoring normal gene expression in acute leukemias.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:37.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) with NPM1 mutation or MLL rearrangement"},{"name":"Acute lymphoblastic leukemia (ALL) with MLL rearrangement"}]},"trialDetails":[{"nctId":"NCT04164199","phase":"PHASE3","title":"Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2019-12-19","conditions":"Advanced Malignancies","enrollment":404},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04649385","phase":"PHASE1","title":"BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-03-04","conditions":"Advanced Solid Tumor","enrollment":157},{"nctId":"NCT06029127","phase":"PHASE2","title":"A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-10-23","conditions":"Non-Small Cell Lung Cancer","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BGB-15025","genericName":"BGB-15025","companyName":"BeiGene","companyId":"beigene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BGB-15025 is a study of Tislelizumab, Pamiparib, and Temozolomide in participants with Advanced Malignancies, including Non-small Cell Lung Cancer and Advanced Solid Tumor. The study is conducted by BeOne Medicines, with the identifier NCT04164199.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}